Dimension Therapeutics, Inc. develops a gene therapy platform that focuses on discovering and developing therapeutic products for people living with rare and metabolic diseases associated with the liver. The company's pipeline of programs includes DTX101, a lead gene therapy product candidate designed to deliver FIX gene expression in patients with hemophilia B; and DTX201, a FVIII gene therapy program for the treatment of hemophilia A. Its pipeline programs also comprise DTX301, a gene therapy product candidate for the treatment of ornithine transcarbamylase deficiency; DTX401, a gene therapy program for the treatment of glycogen storage disease type Ia; DTX501, gene therapy program for the treatment of patients with PKU; DTX701, a gene therapy program for the treatment of Wilson disease; and DTX601, a gene therapy program for the treatment of citrullinemia type I. Dimension Therapeutics, Inc. was founded in 2013 and is based in Cambridge, Massachusetts. Dimension Therapeutics, Inc. operates as a subsidiary of Ultragenyx Pharmaceutical Inc.